- Home
- LDI vs RGNX Comparison
LDI vs RGNX Comparison
Compare LDI & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- RGNX
- Stock Information
- Founded
- LDI 2010
- RGNX 2008
- Country
- LDI United States
- RGNX United States
- Employees
- LDI N/A
- RGNX N/A
- Industry
- LDI Finance: Consumer Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDI Finance
- RGNX Health Care
- Exchange
- LDI Nasdaq
- RGNX Nasdaq
- Market Cap
- LDI 402.7M
- RGNX 459.1M
- IPO Year
- LDI 2021
- RGNX 2015
- Fundamental
- Price
- LDI $2.34
- RGNX $9.18
- Analyst Decision
- LDI Sell
- RGNX Strong Buy
- Analyst Count
- LDI 3
- RGNX 12
- Target Price
- LDI $2.60
- RGNX $36.36
- AVG Volume (30 Days)
- LDI 924.1K
- RGNX 886.8K
- Earning Date
- LDI 11-05-2024
- RGNX 11-06-2024
- Dividend Yield
- LDI N/A
- RGNX N/A
- EPS Growth
- LDI N/A
- RGNX N/A
- EPS
- LDI N/A
- RGNX N/A
- Revenue
- LDI $1,013,388,000.00
- RGNX $84,327,000.00
- Revenue This Year
- LDI N/A
- RGNX $7.91
- Revenue Next Year
- LDI $23.17
- RGNX $214.75
- P/E Ratio
- LDI N/A
- RGNX N/A
- Revenue Growth
- LDI 10.36
- RGNX N/A
- 52 Week Low
- LDI $1.52
- RGNX $8.54
- 52 Week High
- LDI $3.71
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- LDI 47.85
- RGNX 43.02
- Support Level
- LDI $2.22
- RGNX $8.87
- Resistance Level
- LDI $2.90
- RGNX $12.11
- Average True Range (ATR)
- LDI 0.16
- RGNX 0.96
- MACD
- LDI -0.02
- RGNX -0.05
- Stochastic Oscillator
- LDI 34.68
- RGNX 17.17
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.